Advertisement
Singapore markets closed

  • Straits Times Index

    3,348.87
    +12.28 (+0.37%)
     

  • S&P 500

    5,265.73
    -11.78 (-0.22%)
     

  • Dow

    38,493.17
    -193.15 (-0.50%)
     

  • Nasdaq

    16,758.23
    +23.21 (+0.14%)
     

  • Bitcoin USD

    69,094.82
    +960.73 (+1.41%)
     

  • CMC Crypto 200

    1,488.19
    +20.25 (+1.38%)
     

  • FTSE 100

    8,276.39
    +1.01 (+0.01%)
     

  • Gold

    2,364.80
    +19.00 (+0.81%)
     

  • Crude Oil

    74.90
    -2.09 (-2.71%)
     

  • 10-Yr Bond

    4.4180
    -0.0960 (-2.13%)
     

  • Nikkei

    38,923.03
    +435.13 (+1.13%)
     

  • Hang Seng

    18,403.04
    +323.43 (+1.79%)
     

  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     

  • Jakarta Composite Index

    7,036.19
    +65.46 (+0.94%)
     

  • PSE Index

    6,470.74
    +37.64 (+0.59%)
     

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics, Inc.
·1-min read
Relay Therapeutics, Inc.
Relay Therapeutics, Inc.

CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats:

  • TD Cowen 5th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 28, 2024 at 9:30 a.m. ET

  • Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 8:40 a.m. ET

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.

ADVERTISEMENT

About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com